A Study of LY2409021 in Participants With Different Levels of Kidney Function
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to measure how much of the study drug, LY2409021, gets into the
blood stream and how long it takes the body to get rid of it when given to participants with
different levels of kidney function. There were five study groups. Each participant only
enrolled in one group. Participants in groups 1 through 4 were healthy or have mild,
moderate, or severe kidney disease. They completed one study period lasting about 29 days.
Study group 5 enrolled participants with kidney disease who were on dialysis. They have
completed two study periods which together last about 59 days. Screening was required within
21 days prior to the start of the study for all participants.